Moynihan, Ray
June 2008
BMJ: British Medical Journal (International Edition);6/21/2008, Vol. 336 Issue 7658, p1402
Academic Journal
The article focuses on the issue of key opinion leaders in medicine in Great Britain. It explains that the doctors are paid by the medical industry for their advice on marketing and sales of medicines. The amount of money key opinion leaders are paid for their advice is discussed and comments from a former drug company sales representative are included. The processes by which drug companies employ, train, and pay opinion leaders are examined, including the existence of databases which contain information about opinion leaders and their views. Ways to effectively manage opinion leaders and their compensation are also explored.


Related Articles

  • Should the drug industry use key opinion leaders? Fava, Giovanni A. // BMJ: British Medical Journal (International Edition);6/21/2008, Vol. 336 Issue 7658, p1405 

    The article focuses on the issue of key opinion leaders in the pharmaceutical industry in Great Britain. It presents information about the relationship between the fields of medicine and the medical industry and examines the ethical aspects of marketing prescription medicines. The views in favor...

  • Alliance Life Sciences Releases White Paper: "State and Federal 'Sunshine Acts' Shift Key Opinion Leader Marketing Tactics".  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p303 

    The article reports that the Alliance Life Sciences Consulting Group (ALSCG) has released their "State and Federal Sunshine Acts Shift Key Opinion Leader (KOL) Marketing Tactics" white paper on August 10, 2011. It says that the ALSCG report is aimed to evaluate the effect of non-disclosed paid...

  • Victims of success. PASTERNAK, EDITOR, CEEL // HR Magazine;Oct94, Vol. 39 Issue 10, p32 

    Reports that of the approximately 40 pharmacy benefit managers (PBMs) nationwide, half a dozen companies owned by or affiliated with pharmaceutical companies now dominate the marketplace. PBMs' struggle the meet the demand; Need to monitor PBM performance.

  • Health-care reforms and the pharmaceutical industry. Botheras, Larry // Nature;9/29/1994, Vol. 371 Issue 6496, p460 

    Deals with factors affecting employment prospects for those working in the pharmaceutical industry. Cost of drug registration; Granting product licenses.

  • Product management a work in progress. Berek, Richard L. // Pharmaceutical Executive;Mar1998, Vol. 18 Issue 3, p60 

    Presents the results of a survey on the most essential skills and responsibilities of pharmaceutical product managers. Divergence of opinion among managers in setting priorities for skills and responsibilities; Importance of product planning in the business; Importance of obtaining updated...

  • From the Editor. Paul, Reid // Pharmaceutical Representative;Feb2010, Vol. 40 Issue 2, p5 

    The article discusses various reports published within the issue, including one by Chip Moore on pharmaceutical representatives' optimism, Patrick Veroneau's advice for pharmaceutical representatives who are worried of losing their jobs and the need for pharmaceutical representatives to plan for...

  • Chain pharmacy wages rise.  // Drug Store News;1/12/98, Vol. 20 Issue 1, pCP4 

    Reports on an increase in the average hourly wage of licensed pharmacists in Connecticut to $30.63 in 1997.

  • Occupational pay in drug manufacturing.  // Monthly Labor Review;Jan81, Vol. 104 Issue 1, p59 

    Provides data on occupational pay in the drug manufacturing sector in the United States based on a Bureau of Labor Statistics (BLS) survey in September 1978. Weekly averages for biologists, chemists and engineers; Availability of the report, 'Industry Wage Survey, Drug Manufacturing,' from the BLS.

  • New crop of generic leaders face tough governmental issues. Epstein, Debbie // Drug Topics;8/4/97 Supplement, Vol. 141 Issue 15, p10S 

    Profiles a listing of officials that were promoted in the pharmaceutical industry. Information on Alice E. Till, who will assume duties as vice president for scientific affairs at the Generic Pharmaceutical Industry Association; Outline of Nicholas M. Fleischer's responsibilities at the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics